Measurement of intracellular versus extracellular prostate-specific antigen levels in peripheral macrophages: A new approach to noninvasive diagnosis of prostate cancer

Clinical Prostate Cancer

Volumn 3, Issue 3, 2004, Pages 184-188

  Herwig, Ralf ^a   Pelzer, Alexandre ^a   Horninger, Wolfgang ^a   Rehder, Peter ^a   Klocker, Helmut ^a   Ramoner, Reinhold ^a   Pinggera, Germar M ^a   Gozzi, Christian ^a   Konwalinka, Guenther ^a   Bartsch, Georg ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Intracellular staining; Phagocytosis; Screening; Tumor markers

Indexed keywords

CYTOKERATIN; EPITHELIAL MEMBRANE ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CELL DIFFERENTIATION; COHORT ANALYSIS; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATITIS;

EID: 19944368368     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2004.n.029     Document Type: Article

References (17)

1. Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001; 344:1373-1377.
2. Ornstein DK, Kang J. How to improve prostate biopsy detection of prostate cancer. Curr Urol Rep 2001; 2:218-223.
3. Catalona WJ, Richie JP, deKernion JB, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152:2031-2036.
4. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277:1452-1455.
5. Partin AW, Carter HB. The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer. Urol Clin North Am 1996; 23:531-540.
6. Prestigiacomo AF, Stamey TA. Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies? J Urol 1997; 157:189-194.
7. Stenman UH, Paus E, Allard WJ, et al. Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen. Tumour Biol 1999; 20(suppl 1):1-12.
8. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002; 167:2435-2439.
9. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level <=4.0 ng per milliliter. N Engl J Med 2004; 350:2239-2246.
10. Fadlon EJ, Rees RC, McIntyre C, et al. Detection of circulating prostate-specific antigen-positive cells in patients with prostate cancer by flow cytometry and reverse transcription polymerase chain reaction. Br J Cancer 1996; 74:400-405.
11. Fadlon EJ, Hamdy FC. The use of flow cytometry and RT-PCR in the detection of circulating PSA-positive cells in prostate cancer. Methods Mol Biol 1998; 92:215-225.
12. Hamdy FC, Lawry J, Anderson JB, et al. Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer. Br J Urol 1992; 69:392-396.
13. Herwig R, Horninger W, Rehder P, et al. Ability of PSA-positive circulating macrophages to detect prostate cancer. Prostate 2004. In press.
14. Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154:407-413.
15. Chybowski FM, Keller JJ, Bergstralh EJ, et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145:313-318.
16. Babaian RJ, Johnston DA, Naccarato W, et al. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol 2001; 165:757-760.
17. Frauscher F, Klauser A, Volgger H, et al. Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection. J Urol 2002; 167:1648-1652.